Outside of these clinical trials, erdafitinib demonstrated some clinical efficacy in a case of FGFR1-EBF2 positive spindle and round cell neoplasm [42] Notably, infigratinib, an FGFR12/3 selective inhibitor, has also been trialled in adults with FGFR-altered recurrent gliomas, where an 6-month PFS rate of 16% and sustained responses of more than a year were observed [127]. This evidence concerns the gene FGFR1 and central nervous system cancer.